Literature DB >> 11096527

Raynaud's Phenomenon.

.   

Abstract

Raynaud's phenomenon may be primary (idiopathic) or secondary. Primary Raynaud's phenomenon is very common in young women, especially in cool climates. Treatment of patients with primary disease is usually much more successful than treatment of patients with secondary disease. Most patients respond to conservative measures. Reassurance that they will not lose digits or limbs is helpful. They should avoid instigating vasospastic attacks, which are usually caused by cold plus pressure on the digits. Reflex sympathetic vasoconstriction can be avoided by wearing warm clothing, including hats. Mittens are more protective than gloves, which separate the fingers. Many patients find chemical hand and foot warmers very useful. Pavlovian conditioning and biofeedback may be helpful if the patient is willing to spend the time. Underlying disease should be treated or instigating causes avoided in secondary Raynaud's phenomenon. In the more severe cases of primary Raynaud's phenomenon as well as in secondary cases, drug therapy is often beneficial. Calcium entry blockers have yielded the best results. Forms of nifedipine with extended action should be prescribed; felodipine or isradipine can be tried if nifedipine cannot be tolerated owing to frequent side effects. When these drugs fail or are not tolerated, sympatholytic drugs (eg, prazosin, reserpine, guanethidine) have benefited some patients. We have not found nitroglycerin preparations to be of benefit. In severe digital ischemia that does not respond to drug therapy, digital artery sympathectomy may help heal digital ulcers. Cervicodorsal sympathectomy is not recommended for upper extremity symptoms, but lumbosacral sympathectomy will often cure vasospastic attacks of the toes.

Entities:  

Year:  2000        PMID: 11096527     DOI: 10.1007/s11936-000-0016-z

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  21 in total

1.  PROGNOSIS IN RAYNAUD'S PHENOMENON AFTER SYMPATHECTOMY.

Authors:  E N JOHNSTON; R SUMMERLY; M BIRNSTINGL
Journal:  Br Med J       Date:  1965-04-10

2.  Inefficacy of diltiazem in the treatment of Raynaud's phenomenon with associated connective tissue disease: a double blind placebo controlled study.

Authors:  J da Costa; J A Gomes; J Espirito Santo; M Queirós
Journal:  J Rheumatol       Date:  1987-08       Impact factor: 4.666

3.  Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon.

Authors:  R J Rodeheffer; J A Rommer; F Wigley; C R Smith
Journal:  N Engl J Med       Date:  1983-04-14       Impact factor: 91.245

4.  Induced vasodilation as a home treatment for Raynaud's disease.

Authors:  J B Jobe; W P Beetham; D E Roberts; G R Silver; R F Larsen; M P Hamlet; J B Sampson
Journal:  J Rheumatol       Date:  1985-10       Impact factor: 4.666

5.  The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon.

Authors:  P Pancera; S Sansone; S Secchi; G Covi; A Lechi
Journal:  J Intern Med       Date:  1997-11       Impact factor: 8.989

6.  The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study.

Authors:  J Leppert; T Jonasson; H Nilsson; I Ringqvist
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

7.  Use of biofeedback training in treatment of Raynaud's disease and phenomenon.

Authors:  D E Yocum; R Hodes; W R Sundstrom; C S Cleeland
Journal:  J Rheumatol       Date:  1985-02       Impact factor: 4.666

8.  Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France.

Authors:  H R Maricq; P H Carpentier; M C Weinrich; J E Keil; A Franco; P Drouet; O C Ponçot; M V Maines
Journal:  J Rheumatol       Date:  1993-01       Impact factor: 4.666

Review 9.  Angiotensin converting enzyme inhibitors in Raynaud's phenomenon.

Authors:  V F Challenor
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

10.  Skin capillary blood flow in scleroderma.

Authors:  E C LeRoy; J A Downey; P J Cannon
Journal:  J Clin Invest       Date:  1971-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.